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INTRODUCTION
Lung development is governed by complex interactions between
embryonic lung endoderm, mesoderm and mesothelium. During
the pseudoglandular stage of lung development [embryonic day (E)
9.5-16 in the mouse], fibroblast growth factor 9 (encoded by Fgf9)
is expressed in the mesothelium, the single layer of cells that
envelopes the lung, and in the pulmonary epithelium that will give
rise to the proximal conducting airways and terminal epithelial
buds (Colvin et al., 1999). In the absence of FGF9 (Fgf9–/–), lung
development is severely impaired, resulting in perinatal death
(Colvin et al., 2001a; White et al., 2006). Fgf9–/– embryos show
decreased mesenchymal proliferation and impaired epithelial
branching. FGF9 primarily signals to mesenchymal FGF receptors
(FGFRs) 1 and 2, but also has the unique ability to activate
epithelial FGFR signaling (del Moral et al., 2006; White et al.,
2006; Yin et al., 2008).
Lung mesenchyme is not a homogeneous tissue, and using
histological criteria and molecular markers it can be subdivided
into sub-mesothelial (SMM) and sub-epithelial (SEM) domains
(White et al., 2006). The pulmonary vasculature appears to form
between these mesenchymal domains (White et al., 2006; White et
al., 2007). SMM is marked by expression of Wnt2a, and SEM
expresses Noggin (Nog) (Levay-Young and Navre, 1992; Bellusci
et al., 1996; Weaver et al., 2003; Yin et al., 2008). Previous studies
have identified interactions between FGF signaling and WNT/-
catenin signaling in lung mesenchyme that function to positively
reinforce each other. Mesenchymal FGF signaling is required for
expression of WNT2a and mesenchymal WNT/-catenin signaling,
and mesenchymal WNT/-catenin signaling is required to sustain
expression of FGFR1 and FGFR2 (De Langhe et al., 2008; Yin et
al., 2008; Yi et al., 2009). In the absence of either FGF9 or
mesenchymal WNT/-catenin signaling, lung mesenchyme cannot
be rescued by addition of exogenous FGF9 (Yin et al., 2008). This
loss of responsiveness of mesenchyme is likely to be due to
degeneration of this feed-forward loop and loss of FGFR
expression in mesenchyme. In addition to mesothelial and
epithelial Fgf9 and mesenchymal Wnt2a, Wnt7b (which is
expressed in developing epithelium) is also required for lung
development where it activates mesenchymal and, potentially,
epithelial WNT/-catenin signaling (Rajagopal et al., 2008). At
early (lung bud) stages of development, Wnt2b is also expressed in
foregut mesenchyme and signals redundantly with Wnt2a in
endoderm to regulate lung bud formation (Goss et al., 2009). The
mechanisms that sustain this feed-forward loop and the relative
contributions of mesothelial and epithelial FGF9 and mesenchymal
WNT2A and epithelial WNT7B are not known.
Here, we show that mesothelial and epithelial FGF9 have
distinct functions during early pseudoglandular stage lung
development. Mesothelial FGF9 is necessary for mesenchymal
FGF signaling, WNT2A expression and mesenchymal growth,
whereas epithelial FGF9 modulates epithelial branching. WNT2A,
and to a much lesser extent WNT7B, functions to maintain
mesenchymal growth through a required permissive action on
mesenchymal FGFR signaling. Consistent with this, we show that
exogenous activation of both FGF and WNT/-catenin signaling
are required to rescue growth of Fgf9–/– lung mesenchyme, and that
mesenchymal WNT/-catenin signaling is a required permissive
factor for FGF signaling. Finally, we show that epithelial and
mesothelial FGF9 and mesenchymal -catenin function to suppress
expression of Noggin in lung mesenchyme, providing a mechanism
for coupling mesenchymal FGF-WNT/-catenin signaling with
epithelial proliferation.
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SUMMARY
Fibroblast growth factor (FGF) 9 is a secreted signaling molecule that is expressed in lung mesothelium and epithelium and is
required for lung development. Embryos lacking FGF9 show mesenchymal hypoplasia, decreased epithelial branching and, by the
end of gestation, hypoplastic lungs that cannot support life. Mesenchymal FGF signaling interacts with -catenin-mediated WNT
signaling in a feed-forward loop that functions to sustain mesenchymal FGF responsiveness and mesenchymal WNT/-catenin
signaling. During pseudoglandular stages of lung development, Wnt2a and Wnt7b are the canonical WNT ligands that activate
mesenchymal WNT/-catenin signaling, whereas FGF9 is the only known ligand that signals to mesenchymal FGF receptors
(FGFRs). Here, we demonstrate that mesothelial- and epithelial-derived FGF9, mesenchymal Wnt2a and epithelial Wnt7b have
unique functions in lung development in mouse. Mesothelial FGF9 and mesenchymal WNT2A are principally responsible for
maintaining mesenchymal FGF-WNT/-catenin signaling, whereas epithelial FGF9 primarily affects epithelial branching. We show
that FGF signaling is primarily responsible for regulating mesenchymal proliferation, whereas -catenin signaling is a required
permissive factor for mesenchymal FGF signaling.
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All mouse strains, including Fgf9+/–, Fgf9f/f (f indicates a floxed allele),
Dermo1-Cre and Shh-cre have been described previously (Colvin et al.,
2001a; Colvin et al., 2001b; Yu et al., 2003; Harfe et al., 2004; Lin et al.,
2006). For conditional inactivation of Fgf9 in lung mesenchyme, mice were
generated with the genotype Dermo1Cre/+, Fgf9f/f (referred to as Fgf9Dermo1)
by mating Dermo1Cre/+, Fgf9f/+ mice with Fgf9f/f mice. Control mice were
of the genotype Dermo1Cre/+; Dermo1Cre/+, Fgf9f/+; Fgf9f/f; or Fgf9f/+, all
of which showed no phenotypic differences from wild-type mice. For
conditional inactivation of Fgf9 in lung epithelium, mice were generated
with the genotype ShhCre/+, Fgf9f/f (referred to as Fgf9Shh) by mating
ShhCre/+, Fgf9f/+ mice with Fgf9f/f mice. Control mice were of the genotype
ShhCre/+; ShhCre/+, Fgf9f/+; Fgf9f/f; or Fgf9f/+, all of which showed no
phenotypic differences from wild-type mice. All loss-of-function mice
were maintained on a mixed 129SV/J-C57B6/J background.
Analyses of mouse embryos, histology and
immunohistochemistry
Embryo tissues were collected in ice-cold PBS, fixed in 4%
paraformaldehyde (PFA) overnight at 4°C, washed with PBS,
photographed and embedded in paraffin prior to sectioning at 5 m. For
histology, slides were stained with Hematoxylin and Eosin (H&E). For
immunohistochemistry, cryosections were rehydrated and treated with
0.3% hydrogen peroxide in methanol for 15 minutes to suppress the
endogenous peroxidase activity. Antigen retrieval was achieved by
microwaving the sections in 10 mM citrate buffer for 5 minutes followed
by gradual cooling to room temperature. Sections were incubated overnight
at 4°C with the primary antibodies against BrdU (347580, Becton
Dickinson Immunocytometry Systems, 1:200) or FGF9 (AF-273-NA,
R&D, 1:100) and visualized using Broad Spectrum (AEC) Kit (95-9743,
Zymed Laboratories Inc.) or Vectastain Elite ABC (AEC) kit (PK-4005,
Vector Laboratories). For 5-bromo-2-deoxyuridine (BrdU) analysis,
pregnant females were injected with BrdU at 0.1 mg/g body weight, 2
hours prior to harvest. Embryos were collected in ice-cold PBS, processed
and sectioned as above. All staining patterns are representative of at least
three embryos.
Cell death analysis
Cryosectioned slides, prepared as described above, were assayed by
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
using the In Situ Cell Death Detection Kit (Roche Applied Science). Slides
were mounted with DAPI containing Vectashield mounting medium (H-
1200, Vector Laboratories) for fluorescent detection. All staining patterns
are representative of at least three embryos.
Whole mount in situ hybridization
In situ hybridization probes were from the following sources: Lef1
(Kratochwil et al., 1996); Wnt2a (A. McMahon, Harvard University,
Cambridge, MA, USA); Wnt7b (F. Long, Washington University, St Louis,
MO, USA); Noggin (R. Harland, University of California, Berkeley, CA,
USA); Fgf10 (Bellusci et al., 1997); Spry2 (Minowada et al., 1999); Fgfr2
(Yu et al., 2003), Evt4 (Chen et al., 2005); N-Myc (E. Morrisey, University
of Pennsylvania, Philadelphia, PA, USA). Probes were synthesized and
labeled with a kit from Roche Applied Science. Whole-mount in situ
hybridization was performed as described (Colvin et al., 2001a). Following
color reaction and methanol dehydration, tissues were photographed and then
cryosectioned (6 m), mounted on slides and re-photographed. In situ
hybridizations of tissue sections were performed as previously described
(Colvin et al., 1999). All staining patterns are representative of at least three
embryos.
Whole-mount lacZ staining
Lungs were dissected in ice-cold PBS and fixed with 0.5% glutaraldehyde
in PBT (PBS, 0.1% Tween-20) overnight at 4°C. Tissues were washed in
PBT twice for 10 minutes prior to incubation with lacZ staining solution
(2 mM MgCl2, 35 mM potassium ferrocyanide, 35 mM potassium
ferricyanide, 1 mg/ml X-Gal in PBT) at room temperature in the dark.
Following adequate color reaction, tissues were again washed twice in PBT
for 10 minutes each to stop the reaction. Samples were then soaked in 30%
sucrose overnight, photographed and then embedded and frozen in OCT
for cryosectioning (6 M). Sections were dried for ~3 hours at room
temperature, washed with PBS and mounted. All staining patterns are
representative of at least three embryos.
Lung organ cultures
Lung explant cultures were performed as described (White et al., 2006).
E11.5 control, Fgf9Dermo1, Fgf9–/– and wild-type embryonic lungs were
dissected and cultured on Transwell filters (Costar, Corning) for 48 hours
at 37°C, 5% CO2. Mouse FGF9 protein (PeproTech) was used at a
concentration of 2.5 g/ml in DMEM supplemented with 2 g/ml heparin.
LiCl and BIO were used at a concentration of 20 mM (Dean et al., 2005)
and 1 M (Meijer et al., 2003), respectively.
For morpholino knockdown experiments, E11.5 lung explant cultures
were prepared as above. Explants were treated with control (CCTC -
TTACCTCAGTTACAATTTATA), Wnt2a (CCAGGAGAAGGAGACT-
CACTTCGGA), Wnt7b (AGGCCCAGAGACGCCCTTACCTACT), or
Wnt2a and Wnt7b morpholino oligonucleotides (Gene Tools) at a final
 concentration of 10 M in culture media. Morpholinos penetrated the
epithelium and the mesenchyme of lung explant tissue and effectively
blocked mRNA splicing as demonstrated by RT-PCR 48 hours post-
explant (Fig. 5A). Primers were designed to detect the 5 end of the Wnt2a
transcript (forward primer: CGCACACGGAGTCTGACCTGATGTA,
reverse primer: CTTTCTTCTTTGGATCACAGGAGCAG) and the
Wnt2a splice site that is targeted by the morpholino (junction primers)
(forward primer: GAACCAGGGTGGCACTGGCTTCAC, reverse
primer: GATGTGATGCGTGCCATTGGCCTGC). Similar primers were
designed to analyze the Wnt7b transcript: Wnt7b 5 primers (forward
primer: CCCTCCGGCCGCAGCTGTTGG, reverse primer: ACAAT-
GATGGCATCGGGTCGGCTCT), Wnt7b splice junction primers
(forward primer: TCCTCTACGTGAAGCTCGGAGCATT, reverse
primer: CCGTGATGGCATAGGTGAAGGCAG).
To quantify mesenchymal thickness, explants were photographed and
mesenchymal thickness was measured using Canvas X software. Data
shown is representative of at least three independent experiments. P-values
were calculated using the Student’s t-test and mean ± s.d. were plotted.
Quantitative RT-PCR
Total RNA was extracted from individual control, Fgf9Dermo1 or Fgf9Shh
E12.5 embryonic lungs (n3 pooled samples for each genotype, each
pooled sample contained four to six lungs) using the RNeasy kit (Qiagen)
following manufacturer’s instructions. Total RNA was reverse-transcribed
using the iScript Select cDNA Synthesis Kit (BIO-RAD) following the
manufacturer’s recommendations. Quantitative RT-PCR was performed on
an ABI 7500 machine using TaqMan probes for Gapdh (ABI
Mm99999915_g1), Fgf10 (ABI Mn00433275_m1) and Noggin (ABI
Mm00476456_s1). Amplification and analysis were performed according
to the manufacturer’s instructions. All reactions were normalized to Gapdh.
Results were plotted as relative expression compared with control, where
control was scaled to one. P-values were calculated using the Student’s t-
test and mean ± s.d. were plotted.
RESULTS
Mesothelial and epithelial FGF9 have unique
functions in developing lung
During pseudoglandular lung development, Fgf9 is expressed
exclusively in mesothelium and epithelium, but not in
mesenchyme. To explore the role of mesothelial and epithelial
FGF9, tissue-specific Cre recombinases were used to inactivate a
floxed allele of Fgf9 (Fgf9f/f) (Lin et al., 2006) in mesothelial and
epithelial tissues. To inactivate Fgf9 in mesothelium, embryos were
generated with the genotype Dermo1Cre/+, Fgf9f/f (Fgf9Dermo1). The
Dermo1Cre allele targets lung mesenchyme and mesothelium
beginning before E9.5, but has no detectable activity in lung
epithelium (Fig. 1A) (White et al., 2006). Thus, the Dermo1Cre
allele can be used to specifically inactivate mesothelial Fgf9.











Examination of FGF9 expression in Fgf9Dermo1 lungs by
immunohistochemistry showed loss of expression in lung
mesothelium, but retained expression in lung epithelium (Fig. 1D).
Control (Fgf9f/f and Dermo1Cre/+) lung tissue showed FGF9
staining in both epithelium and mesothelium (Fig. 1C).
Fgf9Dermo1 embryos were born alive but only 67% of the
expected number survived beyond weaning. Littermate control
mice were phenotypically normal. At E12.5, Fgf9Dermo1 embryos
had hypoplastic lungs with a normal number and orientation of
lobes and a normal number of epithelial branches (Fig. 1F,L).
Histological examination of Fgf9Dermo1 lungs showed hypoplastic
mesenchyme (Fig. 1H,I). At E13.5 and E14.5, Fgf9Dermo1 lungs
were smaller than control lungs, the edges were serrated and
hypoplastic, and the histology indicated decreased mesenchyme
and decreased epithelial branching (see Fig. S1A,C,E,F in the
supplementary material).
To inactivate Fgf9 in epithelium, embryos were generated with
the genotype ShhCre/+, Fgf9f/f (Fgf9Shh). The ShhCre allele targets
lung epithelium beginning before E9.5, but has no detectable
activity in lung mesenchyme or mesothelium (Fig. 1B) (Harfe et
al., 2004; Harris et al., 2006). Thus, the ShhCre allele can be used
to specifically inactivate epithelial Fgf9. Examination of FGF9
expression in Fgf9Shh lungs by immunohistochemistry showed
loss of expression in lung epithelium, but retained expression in
lung mesothelium (Fig. 1C,E). Fgf9Shh embryos had a normal
number and orientation of primary lobes. However, at E12.5,
Fgf9Shh lungs were slightly smaller than control (Fgf9f/f and
ShhCre/+) lungs, and, in contrast to Fgf9Dermo1 lungs, Fgf9Shh
lungs showed decreased epithelial branching (Fig. 1G,J-L).
Histological examination of E12.5 Fgf9Shh lungs showed 
fewer epithelial ducts but normal appearing mesenchyme. At
E13.5 and E14.5, Fgf9Shh lungs were noticeably smaller 
than control lungs, but showed smooth edges. Lung 
histology showed normal mesenchymal histology but decreased
epithelial branching (see Fig. S1B,D,G,H in the supplementary
material).
Mesothelial and epithelial FGF9 differentially
affect mesenchymal and epithelial proliferation
at early developmental stages
We hypothesized that changes in cell proliferation could account
for the observed differences in lung phenotypes of Fgf9Dermo1
and Fgf9Shh embryos. At E12.5, Fgf9Dermo1 lungs showed
significantly decreased mesenchymal proliferation but normal
epithelial proliferation (Fig. 2A,B,G). At E14.5, both
mesenchymal and epithelial proliferation was decreased (Fig.
2D,E,H). By contrast, at E12.5, Fgf9Shh lungs showed decreased
epithelial proliferation but normal mesenchymal proliferation
(Fig. 2A,C,G). At E14.5, Fgf9Shh lungs showed decreased
proliferation in both epithelial and mesenchymal compartments
(Fig. 2D,F,H), similar to that observed in Fgf9Dermo1 lungs at this
stage. We also examined cell death by TUNEL labeling. At
E12.5 and E14.5, no significant change in cell death was
detected in Fgf9Dermo1 or Fgf9Shh lung tissues (Fig. 2I-K; data not
shown). This is consistent with previous studies showing that
FGF signaling does not regulate cell survival at these stages of
lung development (Yin et al., 2008).
Taken together, these data demonstrate that FGF9 derived from
mesothelial and epithelial tissues have different functions during
early stages (E12.5) of lung development: mesothelial FGF9
functions to maintain lung mesenchymal proliferation, whereas
epithelial FGF9 primarily affects epithelial proliferation. At later
stages (E14.5), both epithelial and mesenchymal compartments
were affected in both conditional knockouts, suggesting that
secondary interactions between tissue compartments might
override these local signals to coordinate growth of lung
mesenchyme and epithelium.
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Fig. 1. Mesothelial and epithelial FGF9 have unique functions in
developing mouse lung. (A,B)lacZ staining for the Rosa26 reporter
(R26R) targeted with Dermo1-Cre (A) and Shh-Cre (B) lungs at E10.5
showing mesenchymal/mesothelial and epithelial cell-specific -gal
staining, respectively. (C-E)Immunohistochemical detection of FGF9 in
E12.5 lung showing expression in epithelium (arrows) and mesothelium
and submesothelial mesenchyme (arrowheads) in control lungs (C).
Fgf9Dermo1 lungs (D) have greatly reduced staining in submesothelial
mesenchyme (arrowheads) and Fgf9Shh lungs (E) have reduced
expression in epithelium (arrows). (F,G)Anterior views of gross
dissections of control (Dermo1-Cre, Fgf9f/+) and Fgf9Dermo1 (F) and
control (Shh-Cre, Fgf9f/+) and Fgf9Shh (G) lungs at E12.5. Note the
decreased mesenchyme but normal epithelial branch number and
orientation of lobes with the Fgf9Dermo1 lung (F) and decreased number
of epithelial branches and normal mesenchyme in Fgf9Shh lung (G). 
(H-K)Hematoxylin and Eosin-stained histological sections of control
(H,J), Fgf9Dermo1 (I) and Fgf9Shh (K) lungs at the same stages as shown in
F,G. (L)Number of epithelial buds in the caudal and left lobes at E12.5.
*P<0.001 (Student’s t-test). Error bars represent s.d. Scale bars: 25m












Mesothelial FGF9 regulates Wnt2a expression and
mesenchymal WNT/-catenin signaling but not
Fgf10 expression or signaling
To examine the effects of mesothelial and epithelial FGF9 on
mesenchymal and epithelial WNT/-catenin signaling, we
examined the expression of mesenchymal Wnt2a, epithelial Wnt7b
and the WNT target gene Lef1 in E12.5 Fgf9Dermo1 and Fgf9Shh
lungs. In the Fgf9Dermo1 lungs, Wnt2a expression was absent in
lung mesenchyme (Fig. 3A,B), similar to what was observed in
Fgf9–/– lungs (Yin et al., 2008). By contrast, in Fgf9Shh lungs,
Wnt2a expression was reduced but still detectable in distal
mesenchyme (Fig. 3A,C,A,C). In control lung, Lef1 was
expressed in both the SMM and SEM domains (Fig. 3D,D). In
Fgf9Dermo1 lungs, Lef1 expression was reduced in the SMM but
retained in the SEM (Fig. 3E,E). By contrast, in Fgf9Shh lungs,
Lef1 expression was reduced in the SEM but retained in the SMM
(Fig. 3F,F). Additionally, Wnt7b and N-Myc (Mycn – Mouse
Genome Informatics) expression was not affected by inactivation
of mesothelial or epithelial Fgf9 (Fig. 3G-I; data not shown). Taken
together, these data are consistent with a model in which
mesothelial FGF9 is the primary source of FGF9 that regulates
mesenchymal FGF-WNT/-catenin signaling.
FGF10 is essential for lung epithelial branching (Bellusci et al.,
1997; Min et al., 1998; Sekine et al., 1999; Weaver et al., 2000).
We hypothesized that the reduced branching observed in Fgf9Shh
lungs could result from reduced Fgf10 expression or signaling.
However, at E12.5, control and Fgf9Shh lungs exhibited comparable
expression patterns and levels of Fgf10 in mesenchyme distal to
budding airways (Fig. 4A-C). Quantitative RT-PCR of Fgf9Shh or
Fgf9Dermo1 E12.5 whole lung, compared with control lung, showed
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Fig. 2. Mesothelial and epithelial FGF9 differentially affect
mesenchymal and epithelial proliferation. (A-F)BrdU labeling of
control (A,D), Fgf9Dermo1 (B,E) and Fgf9Shh (C,F) mouse lung showing
decreased proliferation in the mesenchyme of the Fgf9Dermo1 lung and
the epithelium of the Fgf9Shh lung at E12.5 and E14.5. Note that at
E14.5 proliferation was decreased in both the epithelium and
mesenchyme in Fgf9Dermo1 and Fgf9Shh lung. (G,H)Quantitation of BrdU
labeling at E12.5 (G) and E14.5 (H). *P<0.01 (Student’s t-test). Error
bars represent s.d. (I-K)TUNEL labeling of control (I), Fgf9Dermo1 (J) and
Fgf9Shh (K) lung at E12.5 showing no difference in rates of cell death.
Scale bars: 50m.
Fig. 3. Mesothelial FGF9 regulates WNT2A expression and
mesenchymal WNT/-catenin signaling. (A-C) Expression of Wnt2a
in control (A,A), Fgf9Dermo1 (B) and Fgf9Shh (C,C) mouse lung
mesenchyme at E12.5. A and C are cryosections of the corresponding
whole mounts. Note that in Fgf9Dermo1 lung mesenchyme Wnt2a is not
detected. In Fgf9Shh lung, Wnt2a is still expressed in the distal
mesenchyme (arrow) but not in proximal mesenchyme of epithelium
(e). (D-F) Expression of Lef1 in control (D,D), Fgf9Dermo1 (E,E) and
Fgf9Shh (F,F) lung mesenchyme at E12.5. D, E and F are cryosections
of the corresponding whole mounts. Note that in Fgf9Dermo1 lung, Lef1
expression was detected in the proximal mesenchyme (arrow) and in
Fgf9Shh lung Lef1 was detected in the distal mesenchyme (arrow). 
(G-I)Wnt7b expression in lung epithelium was not significantly changed
in control (G), Fgf9Dermo1 (H) and Fgf9Shh (I) lung epithelium at E12.5.











no significant difference in Fgf10 expression (n3; P0.6 and 0.7,
respectively). Furthermore, Sprouty2 (Spry2), one of the earliest
targets induced in the lung epithelium in response to FGF10 and a
negative regulator of the FGF signaling pathway (Minowada et al.,
1999; Mailleux et al., 2001), showed no significant difference in
expression in control and Fgf9Shh lungs (or Fgf9Dermo1 lungs) at
E12.5 (Fig. 4D-F). Similarly to Spry2, other molecules in the
FGF10 signaling pathway, such as epithelial Fgfr2 (Fig. 4G-I) and
the downstream transcription factor Etv4 (Fig. 4J-L), showed no
significant difference in expression in control and Fgf9Shh (or
Fgf9Dermo1) lungs at E12.5. Note that Fgfr2 expression was absent
in mesenchyme in the Fgf9Dermo1 lung at E12.5. These data suggest
that Fgf10 and the FGF10 signaling pathway is not a primary target
of mesenchymal FGF9 signaling. These data are consistent with
our previous studies in which Fgf10 expression was not
significantly affected in the mesenchyme of Fgf9–/– lungs or -
cateninDermo1 lungs at E12.5 (Colvin et al., 2001a; Yin et al., 2008).
Mesenchymal FGF and WNT/-catenin signaling
suppress Noggin expression
BMP signaling through epithelial ALK3 (BMPR1A – Mouse
Genome Informatics) has been shown to regulate proliferation of
distal lung epithelium (Eblaghie et al., 2006). To determine
whether mesenchymal FGF or WNT/-catenin signaling could
affect the BMP pathway and indirectly epithelial proliferation,
we examined expression of Bmp4 and its inhibitor Noggin. Bmp4
is expressed in distal epithelium and adjacent SEM and Noggin
is expressed in SEM (Weaver et al., 1999; Weaver et al., 2003;
White et al., 2006; Jang et al., 2010). Consistent with previous
observations of E12.5 Fgf9–/– lungs (White et al., 2006), Bmp4
expression was not changed in Fgf9Dermo1 or Fgf9Shh lungs (Fig.
5A-C). However, examination of the BMP inhibitor Noggin
showed significantly increased expression in Fgf9Dermo1 or
Fgf9Shh lungs (Fig. 5D-E), as well as in Fgf9–/– lungs and -
cateninDermo1 conditional knockout lungs (see Fig. S2 in the
supplementary material). This result was also confirmed with
quantitative RT-PCR, which showed significantly increased
expression of Noggin in Fgf9Dermo1 or Fgf9Shh lungs compared
with control lungs (n3; P<0.01, P<0.03, respectively; Fig. 5J).
Interestingly, frozen sections of the whole mounts showed
increased Noggin throughout the mesenchyme of Fgf9Dermo1 and
Fgf9–/– lung, but only in SEM of Fgf9Shh lungs (Fig. 5G-I, see
Fig. S2 in the supplementary material). De-repression of Noggin
and suppression of BMP signaling provides a mechanism by
which loss of mesenchymal FGF or WNT/-catenin signaling
could indirectly lead to decreased epithelial proliferation.
Wnt2a maintains mesenchymal FGF
responsiveness and both Wnt2a and Wnt7b are
required for mesenchymal growth
Wnt2a, Wnt2b and Wnt7b are the only canonical WNT ligands that
are expressed in the developing lung (Shu et al., 2002; Goss et al.,
2009). Wnt2b is expressed at highest levels at the lung bud stage of
development (Lin et al., 2001). Wnt2b–/– mice do not exhibit any
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Fig. 4. FGF10 signaling pathways are not affected by mesothelial
and epithelial FGF9. (A-C)Expression of Fgf10 in control (A),
Fgf9Dermo1 (B) and Fgf9Shh (C) mouse lung mesenchyme at E12.5. 
(D-F)Expression of Spry2 in control (D), Fgf9Dermo1 (E) and Fgf9Shh (F)
lung epithelium at E12.5. No significant differences in Fgf10 or Spry2
expression were observed. (G-I)Expression of Fgfr2 in control (G),
Fgf9Dermo1 (H) and Fgf9Shh (I) lung epithelium at E12.5. (J-L)Expression
of Etv4 in control (J), Fgf9Dermo1 (K) and Fgf9Shh (L) lung mesenchyme at
E12.5. Scale bar: 200m.
Fig. 5. Regulation of BMP pathways by mesothelial and
epithelial FGF9. (A-C)Expression of Bmp4 in control (A), Fgf9Dermo1 (B)
and Fgf9Shh (C) mouse lung mesenchyme at E12.5. (D-F)Expression of
Nog in control (D), Fgf9Dermo1 (E) and Fgf9Shh (F) lung epithelium at
E12.5. Bmp4 expression was similar but Nog expression was
significantly increased in both Fgf9Dermo1 and Fgf9Shh lungs. (G-I)Frozen
sections of the whole mounts shown in D-F. (J)Quantitative RT-PCR
detection of Nog expression showing increased expression in Fgf9Dermo1
and Fgf9Shh E12.5 lung compared with control. Error bars represent s.d.













phenotype, but in combination with knockout of Wnt2a, lung buds
fail to form (Goss et al., 2009). These results suggest that WNT2B
primarily functions at the lung bud stage of development or earlier.
To explore the relative contribution of Wnt2a and Wnt7b to lung
pseudoglandular-stage mesenchyme growth and maintenance 
of mesenchymal FGF signaling, antisense morpholino
oligonucleotides (MOs) were used to inhibit Wnt2a and Wnt7b
mRNA splicing in explanted lung tissue. Treatment of E11.5 lung
explants with antisense MOs for 48 hours did not affect mRNA
expression but effectively blocked mRNA splicing of both the
Wnt2a and Wnt7b transcripts (Fig. 6A). Treatment of lung explants
with Wnt2a MOs resulted in significantly decreased mesenchymal
growth (thickness), which was further enhanced by simultaneous
treatment with Wnt7b MOs (Fig. 6B,D,F,H,J).
Treatment of lung explants with FGF9 resulted in increased
mesenchymal growth and epithelial dilation (del Moral et al., 2006;
White et al., 2006; Yin et al., 2008). To assay mesenchymal
response to FGF signaling following knockdown of Wnt2a and
Wnt7b, explants were treated with MOs and with FGF9. After 48
hours in culture, mesenchymal thickness was measured (Fig.
6C,E,G,I,J). Consistent with previous observations, control lung
explants showed an approximate twofold increase in mesenchymal
thickness following culture with FGF9. Explants treated with a
Wnt7b MO also showed a near-wild-type response to FGF9.
However, explants treated with a Wnt2a MO, or with both Wnt2a
and Wnt7b MOs, did not respond to FGF9. Consistent with loss of
responsiveness to FGF9, mesenchymal Fgfr2 expression assayed
by in situ hybridization was absent in mesenchyme from explants
treated with Wnt2a or with Wnt2a and Wnt7b MOs, but not in
control explants (Fig. 6C,E,I). These data are consistent with a
model in which Wnt2a functions primarily to regulate
mesenchymal WNT/-catenin signaling and expression of
mesenchymal FGFRs. However, Wnt7b has either an indirect or
redundant function with Wnt2a in regulating mesenchymal growth.
Mesenchymal FGF and WNT/-catenin signaling
requires both FGF9 and WNT inputs to maintain
FGF9 responsiveness
Previous studies and data presented here showed that, during the
early stages of mouse lung development, both FGF9 and WNT/-
catenin signaling are required to sustain mesenchymal FGFR
expression and mesenchymal response to FGF9 (De Langhe et al.,
2008; Yin et al., 2008). In the absence of either FGF9 or canonical
WNT ligands, the mesenchymal FGF9-WNT/-catenin feed-
forward network degenerates, resulting in loss of mesenchymal
FGFR expression and FGF responsiveness. A prediction of this
model is that Fgf9–/– lung tissue could be rescued, in terms of
responsiveness to FGF9 and mesenchymal growth, by
simultaneous addition of FGF9 and activation of WNT/-catenin
signaling.
To test the mesenchymal FGF9-WNT/-catenin network model,
control and Fgf9–/– lung explants were treated with the GSK3
inhibitors LiCl or BIO [(2Z,3E)-6-bromoindirubin-3-oxime],
either alone or in combination with FGF9. Treatment of wild-type
lung explants with LiCl or BIO did not affect mesenchymal growth
and did not affect responsiveness to FGF9 (Fig. 7A-C,M). Fgf9–/–
explants failed to respond to FGF9, as previously observed (Yin et
al., 2008) (Fig. 7D,J). However, Fgf9–/– explants treated with LiCl
and FGF9, or BIO and FGF9, showed a 2.6- and 1.8-fold increase,
respectively, in mesenchymal thickness in response to FGF9 (Fig.
7E,K,F,L). Similarly, Fgf9Dermo1 lung explants did not respond to
FGF9 unless simultaneously treated with BIO (see Fig. S3 in the
supplementary material). These data indicate that WNT/-catenin
signaling must be maintained in order to induce or maintain FGFR
expression, FGF9 responsiveness, and continuation of FGF-
WNT/-catenin feed-forward signaling.
DISCUSSION
During lung development, lung mesenchymal cells not only serve
as precursors to stromal fibroblasts and peribronchial and vascular
smooth muscle cells, but they also have a crucial role in regulating
epithelial growth and branching (Morrisey and Hogan, 2010;
Warburton et al., 2010). Although many of the essential signals that
regulate epithelial growth and branching arise from lung
mesenchyme, the mechanisms that regulate and pattern these
signals are poorly understood. Similarly, essential signals that
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Fig. 6. WNT2A and WNT7B are required for mesenchymal
expression of Fgfr2 and response to FGF9. (A)PCR detection of
Wnt2a and Wnt7b mRNA in mouse lung explants treated with control
or splice site morpholinos. Top: amplification of the 5 end of the
transcripts showed normal expression in control, Wnt2a MO and
Wnt7b MO treated explants. Middle: amplification of the splice site (j)
of the transcripts showed reduced or absent mRNA expression in the
corresponding treated explant. (B-I) Wild-type lung explants were
untreated (B,C) or exposed to morpholinos targeting a splice site in the
Wnt2a (D,E), Wnt7b (F,G) or both Wnt2a and Wnt7b (H,I) transcripts
for 48 hours. Explants were also treated with media (B,D,F,H) or FGF9
(C,E,G,I). Expression of Fgfr2 in control (C), Wnt2a (E) and Wnt2a and
Wnt7b MO (I) treated explants showed loss of mesenchymal (asterisks)
Fgfr2 expression following knockdown of Wnt2a or Wnt2a and Wnt7b.
Red lines indicate mesenchymal thickness. (J)Quantification of
mesenchymal width. Explants treated with Wnt2a, or Wnt2a and
Wnt7b MO showed no mesenchymal growth response to FGF9. (n3,











regulate lung mesenchyme have been identified in mesothelium
and epithelium. However, the mechanisms by which extrinsic
signals derived from mesothelium and epithelium regulate
proliferation, differentiation and molecular patterning of lung
mesenchyme are poorly understood.
Mesothelial FGF9 signals to sub-mesothelial
mesenchyme to regulate lung mesenchymal
growth
Previous work from our laboratory and others identified FGF9 as
an essential factor that functions to regulate lung mesenchyme
during early stages of lung development (Colvin et al., 2001a;
Hyatt et al., 2002; Weaver et al., 2003; del Moral et al., 2006;
White et al., 2006; De Langhe et al., 2008; Yin et al., 2008; Yi et
al., 2009). As Fgf9 is expressed in both the mesothelium and
epithelium, we hypothesized that these sources of FGF9 might
have unique and specific regulatory functions. To identify the
relative contributions of Fgf9 derived from mesothelium and
epithelium, we conditionally inactivated the Fgf9 gene in these
tissue compartments. Targeting Fgf9 in mesothelium with Dermo1-
cre demonstrated that mesothelial-derived FGF9 is primarily
responsible for regulating mesenchymal proliferation and has little
influence on epithelial branching. By contrast, epithelial-derived
Fgf9 (targeted with Shh-Cre) influences epithelial branching. Thus,
these two sources of FGF9 must be considered independently when
modeling mechanisms that regulate lung development.
In studies aimed at understanding signaling mechanisms that
operate within lung mesenchyme, we have identified a feed-
forward signaling network in which FGF9 regulates Wnt2a
expression and mesenchymal WNT/-catenin signaling, and in
which mesenchymal WNT/-catenin signaling is required for
mesenchymal FGFR expression and mesenchymal responsiveness
to FGF9 (Yin et al., 2008). Deficiencies of either pathway results
in decreased mesenchymal proliferation.
The question of whether mesenchymal WNT/-catenin signaling
or FGF signaling regulates mesenchymal proliferation directly is
difficult to test owing to the feed-forward relationship of these two
signaling pathways in lung mesenchyme. However, examination of
our data and that from several other studies collectively suggests
that FGF9, but not mesenchymal WNT/-catenin signaling, is the
primary pathway that regulates mesenchymal proliferation. In wild-
type explant cultures, activation of -catenin signaling with either
LiCl or BIO did not affect growth or morphology of the explant
(Fig. 7A-C, see Fig. S3 in the supplementary material). Consistent
with these observations, Rajogopal et al. showed that activation of
-catenin signaling in lung explants (with LiCl) activated Axin2
and Lef1 expression, yet did not affect the size or the morphology
of the explant (Rajagopal et al., 2008). However, in the absence of
mesenchymal FGF signaling (Fgf9–/– explants), activation of WNT
signaling did support mesenchymal growth, but not beyond that of
untreated wild-type explants (Fig. 7D-F,M, see Fig. S3 in the
supplementary material). In contrast to these gain-of-function
studies, morpholino knockdown of Wnt2a alone and of Wnt2a plus
Wnt7b (Fig. 6) and knockout of Wnt2a (Shu et al., 2002) or Wnt7b
(Shu et al., 2002; Rajagopal et al., 2008) resulted in decreased
growth of lung mesenchyme. Given that mesenchymal WNT/-
catenin signaling is required for expression of FGFR1 and FGFR2
(De Langhe et al., 2008; Yin et al., 2008) (Fig. 6), we posit that
mesenchymal WNT/-catenin signaling has a primary permissive
function for FGFR signaling and that FGFR signaling directly
regulates mesenchymal proliferation and differentiation (Fig. 8).
This model posits that mesothelial FGF9 is a key factor for the
regulation of lung growth during development and suggests that
mechanisms that regulate the expression of mesothelial FGF9 will
be crucial for lung development. Although the signals that regulate
Fgf9 expression are not known, the possibility of feedback
regulation by WNT2A signaling to the mesothelium is intriguing.
Studies in endometrial carcinoma cells show that WNT signaling
can regulate Fgf9 expression; however, this signal appears to be
indirect (Hendrix et al., 2006). Other factors that could regulate
mesothelial Fgf9 include biomechanical forces acting on
mesothelial cells, other signaling molecules expressed in the SMM
or signaling molecules expressed in the pleural fluid. Future studies
will be required to determine the mechanisms that regulate Fgf9
expression in the mesothelium.
Epithelial FGF9 signals regulate lung epithelial
branching
The primary consequence of inactivating Fgf9 in lung epithelium is
decreased epithelial branching. The mechanism could include direct
autocrine signaling of FGF9 to epithelium or indirect effects of
epithelial FGF9 on adjacent mesenchyme. Accumulating evidence
suggests that FGF9 can directly affect epithelial growth and
branching. FGF9 can induce proliferation in isolated lung epithelium
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Fig. 7. Mesenchymal FGF and WNT/-catenin signaling requires
both FGF9 and WNT inputs to maintain FGF9 responsiveness. 
(A-L)Lung explant cultures from control (A-C,G-I) and Fgf9–/– (D-F,J-L)
mouse embryos were untreated (A,D,G,J) or treated with LiCl (B,E,H,K)
or BIO (C,F,I,L). Control and Fgf9–/– explants were also treated with
FGF9 (G-L). Red lines indicate mesenchymal thickness. Scale bar:
200m. (M)Quantification of mesenchymal growth in response to LiCl,
BIO and FGF9 (n3 explants for each condition). Dashed red line shows
mesenchymal thickness of wild-type lung explants. Error bars represent












(del Moral et al., 2006) and FGF9 treatment of lung explants in
which mesenchymal FGFRs have been inactivated (either directly
with Dermo1-Cre-mediated targeting of Fgfr genes or indirectly,
secondary to loss of mesenchymal -catenin signaling) results in
epithelial dilation in the absence of a mesenchymal response (Figs 6,
7) (White et al., 2006; Yin et al., 2008).
Indirect mechanisms by which epithelial FGF9 could regulate
epithelial branching could be through the regulation of expression
or activity of mesenchymal-expressed molecules that signal to
epithelium. Candidate pathways include FGF10/FGFR2B and
BMP4/ALK3. FGF10/FGFR2B signaling regulates epithelial
branching (Morrisey and Hogan, 2010). However, the observation
that Fgf10 expression in lung mesenchyme, and Spry2 and Etv4
expression in lung epithelium were not changed in Fgf9Shh lungs
suggests that this pathway is not responsible for the observed
decreased branching.
BMP4 regulates epithelial proliferation through signaling to
BMPR1A (ALK3) (Eblaghie et al., 2006; Sun et al., 2008). The
precise source of BMP4 is controversial. A recent study indicates
that Bmp4 might only be expressed in lung epithelium (Jang et al.,
2010) where it would function as an autocrine factor or as a
paracrine signal to adjacent SEM, but other studies localize Bmp4
to both epithelium and SEM (Weaver et al., 2003). However,
expression of the secreted BMP antagonist Noggin in the SEM
provides a mechanism by which a mesenchymal-expressed factor
can modulate epithelial BMP signaling. Our finding that
mesenchymal FGF and WNT/-catenin signaling functions to
suppress Noggin and that Noggin is highly upregulated in mice
lacking mesenchymal FGF or WNT/-catenin signaling is
consistent with previous studies in which FGF9 beads suppressed
Noggin expression in explant cultures (Weaver et al., 2003) and in
which NogginlacZ expression was increased in distal mesenchyme
of Fgf9–/– lungs (Yi et al., 2009). Specific induction of Noggin in
the SEM of Fgf9Shh lungs might explain the preferential effects on
epithelium observed in this mutant. Future studies will be required
to determine the extent to which mesenchymal FGF-WNT/-
catenin signaling suppression of Noggin affects epithelial
development and which pathway(s) directly regulate Noggin.
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